The present invention provides novel compounds of Formula I and Formula I(a), or the pharmaceutically acceptable salts thereof; their use for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, and processes for preparing compounds of Formula I or Formula I(a).
本发明提供了新型的式 I 和式 I(a)化合物或其药学上可接受的盐;它们在治疗神经系统疾病和神经退行性疾病,尤其是疼痛和偏头痛方面的用途,以及制备式 I 或式 I(a)化合物的工艺。
US7205313B2
申请人:——
公开号:US7205313B2
公开(公告)日:2007-04-17
US7601738B2
申请人:——
公开号:US7601738B2
公开(公告)日:2009-10-13
[EN] METHODS OF TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH OPIATE WITHDRAWAL OR OPIATE RELAPSE<br/>[FR] PROCÉDÉS DE TRAITEMENT OU DE PRÉVENTION D'ÉTATS ASSOCIÉS À UN SEVRAGE AUX OPIACÉS OU À UNE RECHUTE AUX OPIACÉS
申请人:[en]PRONIRAS CORPORATION
公开号:WO2022261282A1
公开(公告)日:2022-12-15
The present disclosure relates to methods of treating or preventing a condition (e.g., a symptom associated with opiate withdrawal or opiate relapse) in a subject, comprising administering to the subject a therapeutically effective amount of tezampanel, a pharmaceutically acceptable salt thereof, or a prodrug thereof.